NCT02695849

Completed

A Study of Prevalence of EGFR Mutations in Participants With...

Hoffmann-La Roche Source

Compare

Other study identifiers

Sponsor study identifier

ML25269

Study Type

observational

Actual enrollment (reported)

69

Locations

1 country

Sites

2

Timeline

Study Start

March 2012

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

May 2015

Actual (reported)

Study Completion

May 2015

Actual (reported)

Brief Summary

This is a non-interventional, local, multicenter, cross-sectional study to determine the prevalence of epidermal growth factor receptor (EGFR) mutations in participants diagnosed with non-squamous non-small cell lung cancer (NSCLC).

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 69 participants
Study completion date: May 2015
Actual (reported)
Listed locations: 1 countries · 2 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
March 2012
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
May 2015
Actual (reported)
Study Completion
May 2015
Actual (reported)
First Submitted
February 25, 2016
Actual (reported)
First Posted
March 1, 2016
Actual (reported)

Last Updated: July 4, 2016
Status Verified: July 2016
Last Update Submitted: July 1, 2016

Conditions

Non-Small Cell Lung Cancer

Keywords

Non-small cell lung cancer (NSCLC)

Outcome Measures

Primary Outcomes (1)

Percentage of Participants with EGFR mutations
Day 1

Secondary Outcomes (1)

Percentage of Participants with types of EGFR mutations
Day 1

Study Arms (1)

NSCLC Participants

Participants with non-squamous NSCLC will be enrolled in this study.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Participants with non-squamous non-small cell lung cancer (NSCLC)

You may qualify if:

Informed consent form signature

Sponsors & Collaborators

Hoffmann-La Roche
Industrylead

Study Sites (2)

Amman, 11941, Jordan

Amman, 13046 / 11942, Jordan

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

Clinical Trials
Hoffmann-La Roche
STUDY DIRECTOR

Enrollment

69 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: CROSS SECTIONAL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

February 25, 2016

First Posted

March 1, 2016

Study Start

March 2012

Date type not reported

This date has not been verified as actual or estimated.

NCT02430974

Chemotherapy of NSCLC With or Without Icotinib

Phase 2Unknown

NCT02044380

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Phase 3Completed

NCT01405079

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

Phase 3Unknown

NCT01255150

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Completed

NCT01801111

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Phase 1/2Completed

NCT02000531

Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population

Phase 4Completed

Jordanian male and female participants greater than or equal to (\>=) 18 years of age

Histologically confirmed NSCLC

Not participating in a study that involves an investigational agent within 30 days prior to enrollment

You may not qualify if:

Other primary malignancy
Fine needle aspiration samples

Contact the study team to confirm eligibility.

Primary Completion

May 2015

Actual (reported)

Study Completion

May 2015

Actual (reported)

Last Updated

July 4, 2016

Record last verified: 2016-07

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02695849
Data provider: ClinicalTrials.gov
Source updated: 2016-07-04
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:20:05 UTC

Locations

JO(2)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

NSCLC Participants

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations